Skip to content
Evigrade
MajorDirect oral anticoagulants (factor Xa inhibitors)×Antituberculous antibiotic

Updated · Methodology

Mechanism

Edoxaban is a substrate of P-glycoprotein (P-gp), an efflux transporter. Rifampicin strongly induces drug-metabolising enzymes and transporters, including P-gp (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA; rifampicin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Rifampicin given with edoxaban lowered the mean edoxaban area under the concentration–time curve (AUC) and shortened its half-life. The effect of edoxaban may weaken (edoxaban SmPC, EMA). In the European Heart Rhythm Association table, edoxaban AUC with rifampicin is 35% lower, while its active metabolites rise to compensate (EHRA 2021). Rifampicin itself can cause vitamin K-dependent coagulopathy and severe bleeding (rifampicin SmPC, AEMPS).

Symptoms

The main risk is weaker protection against clots. In atrial fibrillation, this means ischaemic stroke or systemic embolism, and in venous thromboembolism a recurrence of deep vein thrombosis or pulmonary embolism. Signs include leg swelling and pain, sudden shortness of breath and chest pain, sudden weakness or numbness of an arm, a leg or one side of the face, and difficulty speaking. Bleeding is possible as well. Rifampicin can cause vitamin K-dependent coagulopathy and severe bleeding (rifampicin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Edoxaban itself increases the risk of bleeding, including severe and life-threatening bleeding (edoxaban SmPC, European Medicines Agency, EMA).

Management

Avoid combining edoxaban with rifampicin (edoxaban label, US Food and Drug Administration, FDA). The European edoxaban summary of product characteristics (SmPC) lists rifampicin among the P-glycoprotein (P-gp) inducers that call for caution with edoxaban (edoxaban SmPC, European Medicines Agency, EMA). The European Heart Rhythm Association table also requires caution for this pair, especially with polypharmacy or with two or more interactions that lower anticoagulant levels (EHRA 2021). The dosing section of the edoxaban SmPC lists only reasons to reduce the dose to 30 mg. It gives no specific dose for use with inducers (edoxaban SmPC, EMA). If edoxaban is stopped because of rifampicin, keep anticoagulation continuous and switch to another anticoagulant as the edoxaban SmPC describes (EMA). Stopping an oral anticoagulant early without adequate replacement increases the risk of ischaemic events (edoxaban label, FDA). Rifampicin also lowers exposure to other oral anticoagulants, such as warfarin (rifampicin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Rifampicin can cause vitamin K-dependent coagulopathy, so monitor for it in patients at particular risk of bleeding. Consider vitamin K supplementation in vitamin K deficiency and hypoprothrombinaemia (rifampicin SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Edoxaban

Other interactions with Rifampicin